Completed PHASE2 INTERVENTIONAL 2-arm NCT00967902

Safety and Effectiveness Study of Combo Bio-engineered Sirolimus Eluting Stent (REMEDEE)

The REMEDEE Study: A Prospective, Randomized Study to Evaluate the Safety and Efficacy of an Abluminal Sirolimus Coated Bio-engineered Stent (Combo Bio-engineered Sirolimus Eluting Stent)

Sponsor: OrbusNeich

Conditions Coronary Artery Lesions

Interventions coronary stenting

Updated 6 times since 2017 Last updated: Mar 28, 2016 Started: Nov 30, 2009 Primary completion: Jul 31, 2011 Completion: Sep 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Coronary Artery Lesions and is currently completed. OrbusNeich leads this study, which shows 6 recorded versions since 2009 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Nov 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

OrbusNeich

Data source: OrbusNeich

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Newcastle, Australia